In a patient with known ulcerative colitis who presents with increased stool frequency, urgency, abdominal cramping, and possible rectal bleeding but has a normal fecal calprotectin, how should the flare be evaluated and treated?

Management of UC Flare Symptoms with Normal Calprotectin

In a patient with known ulcerative colitis presenting with flare symptoms but normal fecal calprotectin (<150 mg/g), proceed directly to endoscopic assessment rather than empiric treatment escalation, as normal biomarkers cannot reliably rule out active inflammation in symptomatic patients. 1

Understanding the Diagnostic Dilemma

The 2023 AGA guidelines explicitly address this challenging scenario and provide clear direction:

• Normal fecal calprotectin (<150 mg/g) in symptomatic UC patients has poor negative predictive value – it cannot exclude moderate-to-severe endoscopic inflammation 1
• The sensitivity and specificity of calprotectin <150 mg/g for ruling out active inflammation in patients with mild symptoms is only 78% and 57%, respectively 1
• Up to 49% of patients with endoscopic remission (Mayo 0) still report increased stool frequency, and 9% report rectal bleeding, demonstrating significant symptom-endoscopy discordance 2

Recommended Evaluation Algorithm

Step 1: Exclude Infectious Triggers

• Test stool for Clostridioides difficile and other enteric pathogens before attributing symptoms to IBD flare 1
• Infections can cause UC-like symptoms while calprotectin may remain normal or only mildly elevated 1

Step 2: Assess Symptom Severity

For mild symptoms (slight increase in stool frequency, infrequent rectal bleeding):

• Proceed directly to flexible sigmoidoscopy or colonoscopy rather than relying on biomarkers 1
• The AGA conditionally recommends endoscopic assessment over empiric treatment in this scenario (very low certainty evidence) 1
• Alternative approach: Repeat calprotectin in 3-6 months if patient prefers to avoid endoscopy, but proceed to endoscopy if symptoms persist or worsen 1

For moderate-to-severe symptoms (frequent rectal bleeding, significantly increased stool frequency):

• Still perform endoscopy despite normal calprotectin 1
• Consider checking CRP – if elevated, this increases likelihood of active inflammation even with normal calprotectin 1
• The correlation between symptoms and endoscopic findings is only moderate (Spearman coefficient 0.34-0.39) 2

Step 3: Endoscopic Assessment

• Flexible sigmoidoscopy is sufficient for most UC patients to assess disease activity 3
• Obtain segmental biopsies throughout affected areas 3
• Document Mayo Endoscopic Score 1

Critical Pitfalls to Avoid

Do Not Empirically Escalate Treatment

• The AGA explicitly recommends against empiric treatment adjustment in symptomatic patients with normal biomarkers 1
• Risk of overtreatment with unnecessary immunosuppression and associated complications 1
• Exception: If patient recently underwent treatment adjustment for moderate-to-severe flare and now has mild residual symptoms, biomarkers may inform dose adjustments 1

Recognize Calprotectin Limitations

• Calprotectin has high within-day variability (median coefficient of variation 40%, range 5-114%) in active UC 4
• A single normal value does not exclude inflammation, especially in symptomatic patients 4
• Calprotectin may be falsely normal in isolated proctitis or left-sided disease 3

Consider Alternative Symptom Causes

• Increased stool frequency may persist despite mucosal healing due to:
  • Bile acid malabsorption 2
  • Irritable bowel syndrome overlap 2
  • Functional symptoms 2
• Urgency is common (59% of UC patients) and correlates poorly with calprotectin – only 31% with moderate-severe urgency have calprotectin ≥250 μg/g 5

When Biomarkers and Symptoms Diverge

The evidence reveals important discordance patterns:

• In patients achieving symptomatic remission, 15% still have moderate-to-severe endoscopic inflammation despite normal symptoms 1
• Conversely, 38-49% of patients with endoscopic remission report increased stool frequency 2
• Absence of rectal bleeding is more reliable than stool frequency for identifying endoscopic remission (specificity 84% vs 48%) 2

Monitoring Strategy Post-Endoscopy

If endoscopy confirms remission (Mayo 0-1):

• Continue current therapy 3
• Monitor with patient-reported outcomes plus calprotectin every 6-12 months 3
• Consider functional bowel disorder evaluation if symptoms persist with confirmed mucosal healing 2

If endoscopy reveals active inflammation:

• Escalate therapy based on disease severity and extent 3
• Recheck calprotectin 8-12 weeks after treatment adjustment; target <50 mg/g for confirming endoscopic improvement 1

Special Considerations

Recent treatment adjustment:

• If patient achieved symptomatic remission within 1-3 months of treatment change, calprotectin <50 mg/g (not <150 mg/g) is preferred to confirm endoscopic improvement 1

CRP interpretation:

• Normal CRP is less informative than calprotectin for ruling out inflammation 1
• However, if CRP was elevated during initial flare and has now normalized, this suggests endoscopic improvement 1

Quality of life impact:

• Moderate-severe urgency is associated with 4-fold reduced well-being in UC patients 5
• Symptoms warrant thorough evaluation even with reassuring biomarkers to address quality of life 5